



February 1, 2023

BSE Limited
P. J. Towers, 25th Floor,
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra-Kurla Complex,
Bandra (E)
Mumbai - 400 051

Scrip Code: 530019

Symbol: JUBLPHARMA

Dear Sirs,

Sub.: Schedule of Investor Conference Call for Jubilant Pharmova Limited - Unaudited Financial Results for the quarter ended December 31, 2022

We refer to our letter dated January 27, 2023 regarding schedule of Investor Conference Call, we wish to inform you that the Conference Call scheduled on February 3, 2023 at 5.00 pm has been preponed to 4.00 pm on February 3, 2023. Revised details of the Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully,
For Jubilant Pharmova Limited

Naresh Kapoor
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624




Jubilant Pharmova Limited
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubilantpharmova.com

Noida, Wednesday, 01st, Feb, 2023

Conference call on Friday, Feb 03, 2023 at 04:00 PM IST

Jubilant Pharmova Limited, engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses, will host a conference call for analysts and investors on Friday, Feb 03, 2023, at 04:00 PM IST. The call will commence with a brief management discussion on the financial performance for the quarter ended December 31, 2022, followed by an interactive Question & Answer session.

Diamond Pass Log-In	
Pre-registration:	<p>To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.</p>  Click here to ExpressJoin the Call
	<p>You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.</p>
Conference Dial-In Numbers	
Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Replay Facility:	Available from February 03 to February 10, 2023 Dial in No.: +91 22 7194 5757 / +91 22 6663 5757 Playback ID: 41519

-ENDS -

About Jubilant Pharmova Limited

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is engaged in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses. With a network of 46 radio-pharmacies in the US, Jubilant's Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services. Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU and other geographies) through five manufacturing facilities. The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two world class research centers in India. The company is also involved in the manufacturing of Active Pharmaceutical Products (API) through a US FDA approved facility in Nanjangud, Karnataka. Jubilant Therapeutics (JTI) invested for in-house Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 5,700 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: www.jubilantpharmova.com

For more information please contact:

Surajit Pal, Vineet V Mayer
Jubilant Pharmova Limited
Ph: +91-120 4361002, 1103
E-mail: surajit.pal1@jubl.com
vineet.mayer@jubl.com

Siddharth Rangnekar / Mit Shah
CDR India
Ph: +91 97699 19966 / 99201 68314
E-mail: siddharth@cdr-india.com
mit@cdr-india.com

Disclaimer: *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*
